FDA okays start of BrainStorm stem cell trial in ALS patients
Date Posted: Sunday, April 27, 2014The U.S. Food and Drug Administration approved the start of a mid-stage clinical trial of BrainStorm Cell Therapeutics’ adult stem cell treatment for patients with amyotrophic lateral sclerosis (ALS). The Phase 2 trial will be launched initially at the UMass Chan Medical School.
Reuters
Market Watch
MedCity News